Does in vivo CRISPR-Cas9 genome editing targeting the Pcsk9 gene reduce blood cholesterol levels in mice?
In vivo CRISPR-Cas9 genome editing successfully disrupts the Pcsk9 gene and lowers blood cholesterol in mice, suggesting therapeutic potential for cardiovascular disease prevention.
Genome editing with the CRISPR-CRISPR-associated 9 system disrupts the Pcsk9 gene in vivo with high efficiency and reduces blood cholesterol levels in mice. This approach may have therapeutic potential for the prevention of cardiovascular disease in humans.
Ding et al. (Wed,) studied this question.